A Randomized, Double Blind Placebo Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Subcutaneous Doses of AMG 570 in Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2017
At a glance
- Drugs MEDI 0700 (Primary)
- Indications Rheumatoid arthritis; Systemic lupus erythematosus
- Focus Adverse reactions; First in man
- Sponsors Amgen
- 01 Dec 2017 Planned End Date changed from 3 Nov 2017 to 30 Mar 2018.
- 01 Dec 2017 Planned primary completion date changed from 3 Nov 2017 to 30 Mar 2018.
- 24 Aug 2017 Planned End Date changed from 26 Oct 2017 to 3 Nov 2017.